Antipsychotic Drugs: Receptor Pharmacology, Schizophrenia Treatment and Clozapine Safety

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance.

Overview

Antipsychotics reduce psychotic symptoms in schizophrenia and are also used for specific bipolar disorder and other indications. Choice requires balancing symptom control with movement disorders, metabolic and cardiovascular risks, prior response and patient preferences. Long-acting injectable forms can support adherence when appropriate [1–3].

Mechanistic classification

  • First-generation agents: haloperidol, chlorpromazine and fluphenazine principally antagonize dopamine D2 receptors, with differing potency and other receptor effects.
  • Second-generation agents: risperidone, paliperidone, olanzapine, quetiapine, ziprasidone and lurasidone have varied dopamine/serotonin receptor profiles; metabolic and extrapyramidal risk differs greatly.
  • D2 partial agonists: aripiprazole, brexpiprazole and cariprazine provide functional dopamine-system modulation instead of pure D2 antagonism.
  • Clozapine: a dibenzodiazepine-derived agent with multiple receptor actions, uniquely important in treatment-resistant schizophrenia; not a phenylpiperazine or ‘benzamide’ [1].

Treatment positioning

Antipsychotic treatment should follow comprehensive assessment and shared decision-making. An adequate trial considers dose, duration, adherence and tolerability. Clozapine is recommended for schizophrenia that has not responded sufficiently to at least two adequate antipsychotic trials, subject to monitoring and specialist oversight. Depot/long-acting injections do not represent a separate receptor-mechanism class [2].

Common and serious adverse effects

D2 blockade can cause acute dystonia, akathisia, drug-induced parkinsonism, hyperprolactinemia and tardive dyskinesia. Some agents cause sedation, orthostatic hypotension, anticholinergic effects or QT prolongation. Olanzapine and clozapine have pronounced weight/metabolic risks; monitor weight/BMI, glucose or HbA1c, lipids, BP and movement symptoms. Neuroleptic malignant syndrome is rare but life-threatening; antipsychotics can increase mortality when used for dementia-related psychosis and require careful justification [1,2].

Clozapine: 2025 FDA change

The FDA eliminated the clozapine REMS program effective June 13, 2025 in the United States: mandatory REMS enrollment and ANC submission for dispensing no longer apply. However, severe neutropenia remains a boxed warning and absolute neutrophil count monitoring remains necessary under product labeling. Clozapine also carries risks of myocarditis, cardiomyopathy, severe constipation/ileus, seizures, metabolic effects and pneumonia. Smoking changes may affect CYP1A2-mediated clozapine exposure [3].

Interactions and special populations

Strong CYP inducers or inhibitors may substantially alter specific antipsychotic concentrations. Concomitant sedatives increase falls and respiratory risks. For pregnancy and lactation, individualize treatment rather than automatically stopping maintenance drugs, and monitor newborn effects when applicable. Review cardiac risks, liver and kidney function, and the need for repeat ECG or laboratory monitoring by product [1,2].

Clinical takeaway

Antipsychotic medicines are not interchangeable by generation alone; choose based on response, adverse-effect profile and monitoring. Updated U.S. REMS status should never be confused with removal of the underlying hematologic risk [3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Available from: https://www.nice.org.uk/guidance/cg178/chapter/recommendations
  3. US Food and Drug Administration. FDA removes risk evaluation and mitigation strategy program for clozapine. Drug Safety Communication. 2025 Aug 27. Available from: https://www.fda.gov/drugs/drug-safety-communications/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *